Meeting Banner
Abstract #4238

Prediction of IDH Mutation Status of Diffuse-Gliomas Based on Short-Echo Time Magnetic Resonance Spectroscopy at 3T

Esin Ozturk-Isik1, Sevim Cengiz1, Koray Ozduman2,3, Alpay Ozcan3,4, Cengiz Yakicier5, M. Necmettin Pamir2,3, and Alp Dincer3,6

1Institute of Biomedical Engineering, Bogazici University, Istanbul, Turkey, 2Department of Neurosurgery, Acibadem University, Istanbul, Turkey, 3Neuroradiology Research Center, Acibadem University, Istanbul, Turkey, 4Department of Medical Engineering, Acibadem University, Istanbul, Turkey, 5Department of Molecular Biology and Genetics, Acibadem University, Istanbul, Turkey, 6Department of Radiology, Acibadem University, Istanbul, Turkey

The tumor biology of diffuse-gliomas is best reflected by their molecular profile. Isocitrate dehydrogenase (IDH) mutation status has the strongest correlation to treatment response and patient survival among all molecular markers. The aim of this study is to predict IDH mutation status of gliomas based on short-echo time MR spectroscopic (MRS) biomarkers by using machine learning algorithms at 3T. Our results indicated that MRS based biomarkers were able to discriminate between IDH-mutant and IDH-wild type patients with up to 91% sensitivity, %78 specificity, and 86.9% accuracy by using an ensemble of bootstrap-aggregated decision trees classification with a three-fold cross validation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here